Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 1 clinical study titled A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer. The study aims to assess adverse events and changes in disease activity with the investigational drug ABBV-324 in adult participants with hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). This study is significant as HCC and lung cancer are leading causes of cancer-related deaths worldwide.
The study tests ABBV-324, an intravenous infusion drug, and compares it to lenvatinib, an oral capsule. ABBV-324 is being developed to treat HCC and LUSC, with the goal of determining its safety and efficacy.
The study is interventional, randomized, and follows a sequential intervention model with no masking. Its primary purpose is treatment, focusing on the safety and efficacy of ABBV-324.
The study began on April 14, 2025, with an estimated duration of approximately 6.5 years. The last update was submitted on July 14, 2025. These dates are crucial for tracking the study’s progress and for investors to gauge potential market entry timelines.
This study update could positively influence AbbVie’s stock performance by showcasing its commitment to advancing cancer treatment. However, investor sentiment may also depend on the competitive landscape and the success of similar studies by other companies.
The study is ongoing, and further details are available on the ClinicalTrials portal.